Advances in the treatment of multiple myeloma: The role of thalidomide

被引：6

作者：

Ribas, C ^{[1
]}

Colleoni, GWB ^{[1
]}

机构：

[1] Univ Fed Sao Paulo, EPM, Dept Med, Discipline Hematol & Hemotherapy, Sao Paulo, Brazil

来源：

LEUKEMIA & LYMPHOMA | 2003年 / 44卷 / 02期

关键词：

multiple myeloma; thalidomide; treatment; review;

D O I：

10.1080/1042819021000035671

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Multiple myeloma (MM) accounts for 1% of all malignancies and 10% of malignant hematological neoplasms. In spite of high-dose therapy with stem cell rescue, relapse and disease resistance are common events in the course of the disease. Thalidomide (Thal) has been successfully used in such situations and it's use has also been expanded to the up-front therapy and as adjuvant to stem cell transplantation. Here, we review the underlying concepts and current clinical data regarding Thal in the treatment of MM.

引用

页码：291 / 298

页数：8

共 57 条

[21] PROGNOSTIC FACTORS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR MULTIPLE-MYELOMA [J].

GAHRTON, G ;

TURA, S ;

LJUNGMAN, P ;

BLADE, J ;

BRANDT, L ;

CAVO, M ;

FACON, T ;

GRATWOHL, A ;

HAGENBEEK, A ;

JACOBS, P ;

DELAURENZI, A ;

VANLINT, M ;

MICHALLET, M ;

NIKOSKELAINEN, J ;

REIFFERS, J ;

SAMSON, D ;

VERDONCK, L ;

DEWITTE, T ;

VOLIN, L .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (06) :1312-1322

[22] Cancer statistics, 2000 [J].

Greenlee, RT ;

Murray, T ;

Bolden, S ;

Wingo, PA .

CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33

[23] COMBINATION CHEMOTHERAPY VERSUS MELPHALAN AND PREDNISOLONE IN THE TREATMENT OF MULTIPLE-MYELOMA - AN OVERVIEW OF PUBLISHED TRIALS [J].

GREGORY, WM ;

RICHARDS, MA ;

MALPAS, JS .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (02) :334-342

[24]

Grosbois B, 2001, BLOOD, V98, p163A

[25] Multiple myeloma: Increasing evidence for a multistep transformation process [J].

Hallek, M ;

Bergsagel, PL ;

Anderson, KC .

BLOOD, 1998, 91 (01) :3-21

[26] Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [J].

Hideshima, T ;

Chauhan, D ;

Shima, Y ;

Raje, N ;

Davies, FE ;

Tai, YT ;

Treon, SP ;

Lin, B ;

Schlossman, RL ;

Richardson, P ;

Muller, G ;

Stirling, DI ;

Anderson, KC .

BLOOD, 2000, 96 (09) :2943-2950

[27] Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma [J].

Juliusson, G ;

Celsing, F ;

Turesson, I ;

Lenhoff, S ;

Adriansson, M ;

Malm, C .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :89-96

[28]

Kropff MH, 2000, BLOOD, V96, p168A

[29] Diagnostic challenges and standard therapy [J].

Kyle, RA .

SEMINARS IN HEMATOLOGY, 2001, 38 (02) :11-14

[30] Therapeutic application of thalidomide in multiple myeloma [J].

Kyle, RA ;

Rajkumar, SV .

SEMINARS IN ONCOLOGY, 2001, 28 (06) :583-587

← 1 2 3 4 5 6 →